6 O
ADVERSE O
REACTIONS O
The O
following O
adverse O
reactions O
are O
discussed O
in O
more O
detail O
in O
other O
sections O
of O
the O
labeling O
. O

* O
Hypersensitivity B-OSE_Labeled_AE
[ O
see O
Contraindications O
( O
4 O
) O
] O
* O
Myelosuppression B-OSE_Labeled_AE
, O
Immunosuppression B-OSE_Labeled_AE
, O
Bone B-OSE_Labeled_AE
Marrow I-OSE_Labeled_AE
Failure I-OSE_Labeled_AE
, O
and O
Infections B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Urinary B-OSE_Labeled_AE
Tract I-OSE_Labeled_AE
and O
Renal O
Toxicity I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Cardiotoxicity B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Pulmonary B-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Secondary B-OSE_Labeled_AE
Malignancies I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
* O
Veno B-OSE_Labeled_AE
- I-OSE_Labeled_AE
occlusive I-OSE_Labeled_AE
Liver I-OSE_Labeled_AE
Disease I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
* O
Embryo B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Fetal I-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
* O
Reproductive B-OSE_Labeled_AE
System I-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
and O
Use O
in O
Specific O
Populations O
( O
8.4 O
and O
8.6 O
) O
] O
* O
Impaired B-OSE_Labeled_AE
Wound I-OSE_Labeled_AE
Healing I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
* O
Hyponatremia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.10 O
) O
] O
EXCERPT O
: O
Adverse O
reactions O
reported O
most O
often O
include O
neutropenia O
, O
febrile O
neutropenia O
, O
fever O
, O
alopecia O
, O
nausea O
, O
vomiting O
, O
and O
diarrhea O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Baxter O
Healthcare O
at O
1-866-888-2472 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Common O
Adverse O
Reactions O
Hematopoietic O
system O
: O
Neutropenia B-OSE_Labeled_AE
occurs O
in O
patients O
treated O
with O
cyclophosphamide O
. O

The O
degree O
of O
neutropenia B-NonOSE_AE
is O
particularly O
important O
because O
it O
correlates O
with O
a O
reduction B-NonOSE_AE
in I-NonOSE_AE
resistance I-NonOSE_AE
to I-NonOSE_AE
infections I-NonOSE_AE
. O

Fever B-NonOSE_AE
without O
documented O
infection B-NonOSE_AE
has O
been O
reported O
in O
neutropenic B-NonOSE_AE
patients O
. O

Gastrointestinal O
system O
: O
Nausea B-OSE_Labeled_AE
and O
vomiting B-OSE_Labeled_AE
occur O
with O
cyclophosphamide O
therapy O
. O

Anorexia B-OSE_Labeled_AE
and O
, O
less O
frequently O
, O
abdominal B-OSE_Labeled_AE
discomfort I-OSE_Labeled_AE
or O
pain O
and O
diarrhea B-OSE_Labeled_AE
may O
occur O
. O

There O
are O
isolated O
reports O
of O
hemorrhagic B-OSE_Labeled_AE
colitis I-OSE_Labeled_AE
, O
oral B-OSE_Labeled_AE
mucosal I-OSE_Labeled_AE
ulceration I-OSE_Labeled_AE
and O
jaundice B-OSE_Labeled_AE
occurring O
during O
therapy O
. O

Skin O
and O
its O
structures O
: O
Alopecia B-OSE_Labeled_AE
occurs O
in O
patients O
treated O
with O
cyclophosphamide O
. O

Skin B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
occurs O
occasionally O
in O
patients O
receiving O
the O
drug O
. O

Pigmentation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
the I-OSE_Labeled_AE
skin I-OSE_Labeled_AE
and O
changes O
in O
nails O
can O
occur O
. O

6.2 O
Postmarketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
identified O
from O
clinical O
trials O
or O
post-marketing O
surveillance O
. O

Because O
they O
are O
reported O
from O
a O
population O
from O
unknown O
size O
, O
precise O
estimates O
of O
frequency O
can O
not O
be O
made O
. O

Cardiac B-NonOSE_AE
: O
cardiac B-OSE_Labeled_AE
arrest I-OSE_Labeled_AE
, O
ventricular B-OSE_Labeled_AE
fibrillation I-OSE_Labeled_AE
, O
ventricular B-OSE_Labeled_AE
tachycardia I-OSE_Labeled_AE
, O
cardiogenic B-OSE_Labeled_AE
shock I-OSE_Labeled_AE
, O
pericardial B-OSE_Labeled_AE
effusion I-OSE_Labeled_AE
( O
progressing O
to O
cardiac B-OSE_Labeled_AE
tamponade I-OSE_Labeled_AE
) O
, O
myocardial B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
, O
cardiac B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
( O
including O
fatal B-NonOSE_AE
outcomes O
) O
, O
cardiomyopathy B-OSE_Labeled_AE
, O
myocarditis B-OSE_Labeled_AE
, O
pericarditis B-OSE_Labeled_AE
, O
carditis B-OSE_Labeled_AE
, O
atrial B-OSE_Labeled_AE
fibrillation I-OSE_Labeled_AE
, O
supraventricular B-OSE_Labeled_AE
arrhythmia I-OSE_Labeled_AE
, O
ventricular B-OSE_Labeled_AE
arrhythmia I-OSE_Labeled_AE
, O
bradycardia B-OSE_Labeled_AE
, O
tachycardia B-OSE_Labeled_AE
, O
palpitations B-OSE_Labeled_AE
, O
QT B-OSE_Labeled_AE
prolongation I-OSE_Labeled_AE
. O

Congenital B-NonOSE_AE
, I-NonOSE_AE
Familial I-NonOSE_AE
and I-NonOSE_AE
Genetic I-NonOSE_AE
: O
intra B-OSE_Labeled_AE
- I-OSE_Labeled_AE
uterine I-OSE_Labeled_AE
death I-OSE_Labeled_AE
, O
fetal B-OSE_Labeled_AE
malformation I-OSE_Labeled_AE
, O
fetal B-OSE_Labeled_AE
growth I-OSE_Labeled_AE
retardation I-OSE_Labeled_AE
, O
fetal B-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
( O
including O
myelosuppression B-OSE_Labeled_AE
, O
gastroenteritis B-OSE_Labeled_AE
) O
. O

Ear B-NonOSE_AE
and I-NonOSE_AE
Labyrinth I-NonOSE_AE
: O
deafness B-OSE_Labeled_AE
, O
hearing B-OSE_Labeled_AE
impaired I-OSE_Labeled_AE
, O
tinnitus B-OSE_Labeled_AE
. O

Endocrine B-NonOSE_AE
: O
water B-OSE_Labeled_AE
intoxication I-OSE_Labeled_AE
. O

Eye B-NonOSE_AE
: O
visual B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
, O
conjunctivitis B-OSE_Labeled_AE
, O
lacrimation B-OSE_Labeled_AE
. O

Gastrointestinal B-NonOSE_AE
: O
gastrointestinal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
acute B-OSE_Labeled_AE
pancreatitis I-OSE_Labeled_AE
, O
colitis B-OSE_Labeled_AE
, O
enteritis B-OSE_Labeled_AE
, O
cecitis B-OSE_Labeled_AE
, O
stomatitis B-OSE_Labeled_AE
, O
constipation B-OSE_Labeled_AE
, O
parotid B-OSE_Labeled_AE
gland I-OSE_Labeled_AE
inflammation I-OSE_Labeled_AE
. O

General B-NonOSE_AE
Disorders I-NonOSE_AE
and I-NonOSE_AE
Administrative I-NonOSE_AE
Site I-NonOSE_AE
Conditions I-NonOSE_AE
: O
multiorgan B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
general B-OSE_Labeled_AE
physical I-OSE_Labeled_AE
deterioration I-OSE_Labeled_AE
, O
influenza B-OSE_Labeled_AE
- I-OSE_Labeled_AE
like I-OSE_Labeled_AE
illness I-OSE_Labeled_AE
, O
injection B-OSE_Labeled_AE
/infusion O
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
thrombosis O
, O
necrosis O
, O
phlebitis O
, O
inflammation O
, O
pain O
, O
swelling O
, O
erythema O
) O
, O
pyrexia B-OSE_Labeled_AE
, O
edema B-OSE_Labeled_AE
, O
chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
mucosal B-OSE_Labeled_AE
inflammation I-OSE_Labeled_AE
, O
asthenia B-OSE_Labeled_AE
, O
pain B-OSE_Labeled_AE
, O
chills B-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
, O
malaise B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
. O

Hematologic B-NonOSE_AE
: O
myelosuppression B-OSE_Labeled_AE
, O
bone B-OSE_Labeled_AE
marrow I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
disseminated B-OSE_Labeled_AE
intravascular I-OSE_Labeled_AE
coagulation I-OSE_Labeled_AE
and O
hemolytic B-OSE_Labeled_AE
uremic I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
( O
with O
thrombotic B-OSE_Labeled_AE
microangiopathy I-OSE_Labeled_AE
) O
. O

Hepatic B-NonOSE_AE
: O
veno B-OSE_Labeled_AE
- I-OSE_Labeled_AE
occlusive I-OSE_Labeled_AE
liver I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
, O
cholestatic B-OSE_Labeled_AE
hepatitis I-OSE_Labeled_AE
, O
cytolytic B-OSE_Labeled_AE
hepatitis I-OSE_Labeled_AE
, O
hepatitis B-OSE_Labeled_AE
, O
cholestasis B-OSE_Labeled_AE
; O
hepatotoxicity B-OSE_Labeled_AE
with O
hepatic B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
hepatic B-OSE_Labeled_AE
encephalopathy I-OSE_Labeled_AE
, O
ascites B-OSE_Labeled_AE
, O
hepatomegaly B-OSE_Labeled_AE
, O
blood B-OSE_Labeled_AE
bilirubin I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
hepatic B-OSE_Labeled_AE
function I-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
, O
hepatic B-OSE_Labeled_AE
enzymes I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
. O

Immune B-NonOSE_AE
: O
immunosuppression B-OSE_Labeled_AE
, O
anaphylactic B-OSE_Labeled_AE
shock I-OSE_Labeled_AE
and O
hypersensitivity B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
. O

Infections B-NonOSE_AE
: O
The O
following O
manifestations O
have O
been O
associated O
with O
myelosuppression B-OSE_Labeled_AE
and O
immunosuppression B-OSE_Labeled_AE
caused O
by O
cyclophosphamide O
: O
increased O
risk O
for O
and O
severity O
of O
pneumonias B-NonOSE_AE
( O
including O
fatal B-NonOSE_AE
outcomes O
) O
, O
other O
bacterial B-NonOSE_AE
, O
fungal O
, O
viral O
, O
protozoal O
and O
, O
parasitic O
infections I-NonOSE_AE
; O
reactivation B-NonOSE_AE
of O
latent O
infections O
, O
( O
including O
viral I-NonOSE_AE
hepatitis I-NonOSE_AE
, O
tuberculosis O
) O
, O
Pneumocystis B-NonOSE_AE
jiroveci I-NonOSE_AE
, O
herpes B-NonOSE_AE
zoster I-NonOSE_AE
, O
Strongyloides B-NonOSE_AE
, O
sepsis B-NonOSE_AE
and O
septic B-NonOSE_AE
shock I-NonOSE_AE
. O

Investigations B-NonOSE_AE
: O
blood B-OSE_Labeled_AE
lactate I-OSE_Labeled_AE
dehydrogenase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
C B-OSE_Labeled_AE
- I-OSE_Labeled_AE
reactive I-OSE_Labeled_AE
protein I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
. O

Metabolism B-NonOSE_AE
and I-NonOSE_AE
Nutrition I-NonOSE_AE
: O
hyponatremia B-OSE_Labeled_AE
, O
fluid B-OSE_Labeled_AE
retention I-OSE_Labeled_AE
, O
blood B-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
blood B-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
. O

Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
Connective I-NonOSE_AE
Tissue I-NonOSE_AE
: O
rhabdomyolysis B-OSE_Labeled_AE
, O
scleroderma B-OSE_Labeled_AE
, O
muscle B-OSE_Labeled_AE
spasms I-OSE_Labeled_AE
, O
myalgia B-OSE_Labeled_AE
, O
arthralgia B-OSE_Labeled_AE
. O

Neoplasms B-NonOSE_AE
: O
acute B-OSE_Labeled_AE
leukemia I-OSE_Labeled_AE
, O
myelodysplastic B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
lymphoma B-OSE_Labeled_AE
, O
sarcomas B-OSE_Labeled_AE
, O
renal B-OSE_Labeled_AE
cell I-OSE_Labeled_AE
carcinoma I-OSE_Labeled_AE
, O
renal B-OSE_Labeled_AE
pelvis I-OSE_Labeled_AE
cancer I-OSE_Labeled_AE
, O
bladder B-OSE_Labeled_AE
cancer I-OSE_Labeled_AE
, O
ureteric B-OSE_Labeled_AE
cancer I-OSE_Labeled_AE
, O
thyroid B-OSE_Labeled_AE
cancer I-OSE_Labeled_AE
. O

Nervous B-NonOSE_AE
System I-NonOSE_AE
: O
encephalopathy B-OSE_Labeled_AE
, O
convulsion B-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
neurotoxicity B-OSE_Labeled_AE
has O
been O
reported O
and O
manifested O
as O
reversible B-OSE_Labeled_AE
posterior I-OSE_Labeled_AE
leukoencephalopathy I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
myelopathy B-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
, O
polyneuropathy B-OSE_Labeled_AE
, O
neuralgia B-OSE_Labeled_AE
, O
dysesthesia B-OSE_Labeled_AE
, O
hypoesthesia B-OSE_Labeled_AE
, O
paresthesia B-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
, O
dysgeusia B-OSE_Labeled_AE
, O
hypogeusia B-OSE_Labeled_AE
, O
parosmia B-OSE_Labeled_AE
. O

Pregnancy B-NonOSE_AE
: O
premature B-OSE_Labeled_AE
labor I-OSE_Labeled_AE
. O

Psychiatric B-NonOSE_AE
: O
confusional B-OSE_Labeled_AE
state I-OSE_Labeled_AE
. O

Renal B-NonOSE_AE
and I-NonOSE_AE
Urinary I-NonOSE_AE
: O
renal B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
renal B-OSE_Labeled_AE
tubular I-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
renal B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
, O
nephropathy B-OSE_Labeled_AE
toxic I-OSE_Labeled_AE
, O
hemorrhagic B-OSE_Labeled_AE
cystitis I-OSE_Labeled_AE
, O
bladder B-OSE_Labeled_AE
necrosis I-OSE_Labeled_AE
, O
cystitis B-OSE_Labeled_AE
ulcerative I-OSE_Labeled_AE
, O
bladder B-OSE_Labeled_AE
contracture I-OSE_Labeled_AE
, O
hematuria B-OSE_Labeled_AE
, O
nephrogenic B-OSE_Labeled_AE
diabetes I-OSE_Labeled_AE
insipidus I-OSE_Labeled_AE
, O
atypical B-OSE_Labeled_AE
urinary I-OSE_Labeled_AE
bladder I-OSE_Labeled_AE
epithelial I-OSE_Labeled_AE
cells I-OSE_Labeled_AE
. O

Reproductive B-NonOSE_AE
System I-NonOSE_AE
: O
infertility B-OSE_Labeled_AE
, O
ovarian B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
ovarian B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
amenorrhea B-OSE_Labeled_AE
, O
oligomenorrhea B-OSE_Labeled_AE
, O
testicular B-OSE_Labeled_AE
atrophy I-OSE_Labeled_AE
, O
azoospermia B-OSE_Labeled_AE
, O
oligospermia B-OSE_Labeled_AE
. O

Respiratory B-NonOSE_AE
: O
pulmonary B-OSE_Labeled_AE
veno I-OSE_Labeled_AE
- I-OSE_Labeled_AE
occlusive I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
, O
acute B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
distress I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
interstitial B-OSE_Labeled_AE
lung I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
as O
manifested O
by O
respiratory B-NonOSE_AE
failure I-NonOSE_AE
( O
including O
fatal B-NonOSE_AE
outcomes O
) O
, O
obliterative B-OSE_Labeled_AE
bronchiolitis I-OSE_Labeled_AE
, O
organizing B-OSE_Labeled_AE
pneumonia I-OSE_Labeled_AE
, O
alveolitis B-OSE_Labeled_AE
allergic I-OSE_Labeled_AE
, O
pneumonitis B-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
; O
respiratory B-OSE_Labeled_AE
distress I-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
hypertension I-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
pleural B-OSE_Labeled_AE
effusion I-OSE_Labeled_AE
, O
bronchospasm B-OSE_Labeled_AE
, O
dyspnea B-OSE_Labeled_AE
, O
hypoxia B-OSE_Labeled_AE
, O
cough B-OSE_Labeled_AE
, O
nasal B-OSE_Labeled_AE
congestion I-OSE_Labeled_AE
, O
nasal B-OSE_Labeled_AE
discomfort I-OSE_Labeled_AE
, O
oropharyngeal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
rhinorrhea B-OSE_Labeled_AE
. O

Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
: O
toxic B-OSE_Labeled_AE
epidermal I-OSE_Labeled_AE
necrolysis I-OSE_Labeled_AE
, O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
erythema B-OSE_Labeled_AE
multiforme I-OSE_Labeled_AE
, O
palmar B-OSE_Labeled_AE
- I-OSE_Labeled_AE
plantar I-OSE_Labeled_AE
erythrodysesthesia I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
radiation B-OSE_Labeled_AE
recall I-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
, O
toxic B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
eruption I-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
, O
dermatitis B-OSE_Labeled_AE
, O
blister B-OSE_Labeled_AE
, O
pruritus B-OSE_Labeled_AE
, O
erythema B-OSE_Labeled_AE
, O
nail B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
facial B-OSE_Labeled_AE
swelling I-OSE_Labeled_AE
, O
hyperhidrosis B-OSE_Labeled_AE
. O

Tumor B-NonOSE_AE
lysis I-NonOSE_AE
syndrome I-NonOSE_AE
: O
like O
other O
cytotoxic O
drugs O
, O
cyclophosphamide O
may O
induce O
tumor B-OSE_Labeled_AE
- I-OSE_Labeled_AE
lysis I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
and O
hyperuricemia B-OSE_Labeled_AE
in O
patients O
with O
rapidly O
growing O
tumors B-Not_AE_Candidate
. O

Vascular B-NonOSE_AE
: O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
, O
venous B-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
, O
vasculitis B-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
ischemia I-OSE_Labeled_AE
, O
hypertension B-OSE_Labeled_AE
, O
hypotension B-OSE_Labeled_AE
, O
flushing B-OSE_Labeled_AE
, O
hot B-OSE_Labeled_AE
flush I-OSE_Labeled_AE
. O

